Versartis (VSAR) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Versartis Reports Fourth Quarter and Full Year 2015 Financial Results
February 18, 2016 4:05 PM ESTMENLO PARK, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ: VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the fourth quarter and full year ended December 31, 2015.
Over the past year, we have made tremendous progress advancing the development of somavaratan in the US and globally having initiated three late stage clinical trials, commented Jay Shepard, Chief Executive Officer. VELOCITY, our Phase 3 trial for pediatric patients, and VITAL, our Phase 2... More
